Security key
26818M108
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 164,426,217
- Total 13F shares
- 155,774,921
- Share change
- +27,199,325
- Total reported value
- $1,970,440,035
- Put/Call ratio
- 132%
- Price per share
- $12.65
- Number of holders
- 205
- Value change
- +$381,733,004
- Number of buys
- 146
- Number of sells
- 64
Report period
Q3 2025
Institutions
205
Top holders
10
DYN full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 26818M108
Recent filing periods:
Top shareholders of DYN - Dyne Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.8%
from 13D/G
|
8,078,428
|
$76,906,635 | — | 30 Jun 2025 | |
| Forbion Capital Fund IV Cooperatief U.A. |
13D/G
|
ForDyne B.V. |
4.8%
|
5,400,545
|
$60,000,055 | $0 | 31 Mar 2025 | |
| Atlas Venture Fund XI, L.P. |
3/4/5
13D/G
|
10%+ Owner · Atlas Venture Associates XI, L.P. |
4%
from 13D/G
|
6,562,578
|
$165,705,095 | — | 26 Feb 2024 | |
| RTW INVESTMENTS, LP |
13D/G
13F
|
Company |
1.5%
|
1,690,567
|
$18,782,199 | -$39,196,902 | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
1.5%
|
1,669,342
|
$18,546,390 | -$39,187,803 | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
5.9%
|
9,714,392
|
$92,481,012 | — | 30 Jun 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
5.7%
|
9,437,962
|
$89,875,125 | — | 30 Jun 2025 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
5.6%
|
9,130,465
|
$86,922,027 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.7%
|
7,651,157
|
$72,839,014 | — | 30 Jun 2025 | |
| FCPM III SERVICES B.V. |
13F
|
Company |
3.3%
|
5,462,846
|
$52,006,294 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
3.2%
|
5,293,369
|
$50,392,874 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2.9%
|
4,836,437
|
$46,042,880 | — | 30 Jun 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.3%
|
3,766,660
|
$35,858,603 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
3,355,678
|
$31,946,055 | — | 30 Jun 2025 | |
| BRAIDWELL LP |
13F
|
Company |
2%
|
3,273,349
|
$31,162,282 | — | 30 Jun 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.9%
|
3,191,000
|
$30,378,320 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.9%
|
3,086,779
|
$29,386,135 | — | 30 Jun 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.6%
|
2,560,000
|
$24,371,200 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
2,383,953
|
$22,696,000 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
2,253,670
|
$21,458,107 | — | 30 Jun 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.4%
|
2,247,390
|
$21,395,153 | — | 30 Jun 2025 | |
| Venrock Adviser, LLC |
13F
|
Company |
1.3%
|
2,173,913
|
$20,695,652 | — | 30 Jun 2025 | |
| Logos Global Management LP |
13F
|
Company |
1.2%
|
1,900,000
|
$18,088,000 | — | 30 Jun 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.1%
|
1,793,590
|
$17,075,000 | — | 30 Jun 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.92%
|
1,505,984
|
$14,336,968 | — | 30 Jun 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.89%
|
1,455,429
|
$13,855,684 | — | 30 Jun 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.88%
|
1,446,361
|
$13,769,357 | — | 30 Jun 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.85%
|
1,390,140
|
$13,234,131 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.83%
|
1,362,176
|
$12,967,916 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.82%
|
1,340,443
|
$12,761,018 | — | 30 Jun 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.68%
|
1,114,960
|
$10,614,419 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.63%
|
1,031,400
|
$9,818,928 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.57%
|
943,874
|
$8,985,681 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
841,037
|
$8,006,673 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.48%
|
791,987
|
$7,539,716 | — | 30 Jun 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.48%
|
791,120
|
$7,531,462 | — | 30 Jun 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
0.48%
|
789,425
|
$7,515,326 | — | 30 Jun 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.47%
|
770,225
|
$7,332,542 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.45%
|
745,071
|
$7,093,076 | — | 30 Jun 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.45%
|
745,062
|
$7,092,990 | — | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.44%
|
727,500
|
$6,925,800 | — | 30 Jun 2025 | |
| MPM ASSET MANAGEMENT LLC |
13F
|
Company |
0.42%
|
682,376
|
$6,496,220 | — | 30 Jun 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.37%
|
614,865
|
$5,853,515 | — | 30 Jun 2025 | |
| Jain Global LLC |
13F
|
Company |
0.36%
|
596,167
|
$5,675,510 | — | 30 Jun 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.35%
|
580,998
|
$5,531,101 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.35%
|
574,853
|
$5,472,601 | — | 30 Jun 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.34%
|
558,896
|
$5,321,000 | — | 30 Jun 2025 | |
| WASATCH ADVISORS LP |
13F
|
Company |
0.34%
|
557,937
|
$5,311,560 | — | 30 Jun 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.32%
|
524,161
|
$4,990,225 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.31%
|
513,801
|
$4,891,385 | — | 30 Jun 2025 |
Institutional Holders of Dyne Therapeutics, Inc. - Common Stock (DYN) as of Q3 2025
As of 30 Sep 2025,
Dyne Therapeutics, Inc. - Common Stock (DYN) was held by
205 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
155,774,921 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, FCPM III SERVICES B.V., FMR LLC, STATE STREET CORP, Siren, L.L.C., TCG Crossover Management, LLC, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
206
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
195
Q3 2025 holders
205
Holder diff
10
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.